论文部分内容阅读
目的探讨瑞替普酶治疗急性心肌梗死患者的临床疗效。方法收集2013年1月至2014年2月收治的66例急性心肌梗死患者资料,按患者入院治疗时间顺序分为两组,对照组33例患者予以尿激酶治疗,瑞替普酶组33例患者予以瑞替普酶治疗。比较两组患者溶栓后临床再通率、病死率以及并发出血率。结果瑞替普酶组患者临床再通率明显高于对照组(P<0.05);且该组患者并发出血率、病死率均明显低于对照组(均P<0.05)。结论采用瑞替普酶治疗急性心肌梗死具有较高理想的临床治疗效果,且安全性高。
Objective To investigate the clinical efficacy of reteplase in patients with acute myocardial infarction. Methods The data of 66 patients with acute myocardial infarction who were admitted from January 2013 to February 2014 were collected and divided into two groups according to the time sequence of admission to hospital. Thirty-three patients in the control group were treated with urokinase and 33 patients in the control group To reteplase treatment. The clinical recanalization rate, case fatality rate and concurrent bleeding rate were compared between the two groups after thrombolysis. Results The reperfusion rate in reteplase group was significantly higher than that in control group (P <0.05). The rates of concurrent bleeding and mortality in reteplase group were significantly lower than those in control group (all P <0.05). Conclusion Reteplase treatment of acute myocardial infarction with high ideal clinical treatment, and high safety.